Effectiveness of educational intervention carried out by clinical pharmacists for the quality of life of patients with irritable bowel syndrome: A randomized controlled trial

• Main Authors: Vo Duy Thong, Nguyen Ngoc Phuc, Bui Thi Huong Quynh
• Format: Article
• Language: English
• Published: Wiley 2021-02-01
• Series: JGH Open
• Subjects: effectiveness of education; irritable bowel syndrome; quality of life
• Online Access: https://doi.org/10.1002/jgh3.12477

Abstract Background and Aim Irritable bowel syndrome (IBS) is associated with repetitive gastrointestinal symptoms that greatly reduce the patient's quality of life (QoL). Training regarding IBS‐related knowledge, medication adherence, lifestyle, and diet adjustments has been demonstrated to strengthen patient QoL. The aim of this study was to evaluate the effectiveness of an educational intervention carried out by clinical pharmacists to improve the QoL of patients with IBS. Methods Our research included data collected at the University Medical Center, Ho Chi Minh City, from April 2018 to December 2018, and was designed as a randomized controlled clinical trial. Patients with IBS were randomized into an intervention group (IG) and nonintervention group (NIG). The intervention program included training about IBS‐related knowledge, the importance of medication adherence, symptom recognition, lifestyle, and diet adjustments. Participants were followed up by monthly telephone calls. The outcome was the change in patient QoL scores (IBS‐QoL) 8 weeks after they took part in the research. Results Of 273 patients in the trial, there were 132 patients in the IG cohort and 141 in the NIG cohort. At 8 weeks, IG QoL score changes were statistically higher than those of NIG: 20.1 ± 12.1 (IG) versus 13.2 ± 13.4 (NIG). Furthermore, pharmacist intervention played an important role in increasing QoL after 8 weeks, as confirmed by multivariate regression analysis (B = 5.9; 95% confidence interval 2.4–9.4, P = 0.001). Conclusions Patient education, lifestyle, and dietary intervention, administered by clinical pharmacists, improves IBS‐QoL compared to standard medical therapy over 8 weeks.